Issue link: https://viewer.e-digitaledition.com/i/545673
TO MANY SCIENTISTS, improving cognition in people with Down syndrome is a research goal because they believe it will improve the lives of people with the condition. Furthermore, nearly all people with Down syndrome have the brain plaques and tangles associated with Alzheimer's disease by their 40s, but only an estimated 50 percent will get the dementia. Understanding why half are protected may lead researchers to important treatments or even a cure for Alzheimer's. For both of these reasons, researchers are intrigued by medications that might boost learning and memory. In the U.S., there are many layers of protection for humans participating in drug-related research. Therefore, researchers must first prove that pharmaceutical treatments work in genetically engineered mice before testing these drugs on people. Although these mouse models have shown a great deal of promise, they also pose a significant set of limitations for researchers. A SUMMARY OF AVAILABLE STUDIES Down syndrome, or trisomy 21, occurs when a person is born with three copies of chromosome 21, and thus three copies of the 161 protein-coding genes on chromosome 21, instead of two. "We have learned a lot about a small number of these genes, but how many and which genes contribute to cognitive deficits in Down syndrome are not known," said Katheleen Gardiner, Ph.D., Professor in the Department of Pediatrics at the University of Colorado Denver and the Linda Crnic Institute for Down Syndrome. Dr. Gardiner is an internationally known genetics researcher who has dedicated her career to studying Down syndrome. She created the first gene function database for the condition. To date, the most commonly used mouse model in Down syndrome cognition research is the Ts65Dn mouse, which contains copies of 88 protein-coding genes found on a human's chromosome 21. In an exhaustive review of studies on pharmaceutical therapies for improving cognitive function, published in a Dec. 2014 issue of Drug Design, Development, and Therapy, Dr. Gardiner found 31 studies that showed complete or partial recovery of learning and memory in Ts65Dn mice. Among the 23 drugs showing positive benefits were memantine, a drug approved to treat moderate to severe Alzheimer's disease and with known relationships to genes on human chromosome 21; fluoxetine (brand name Prozac), a drug approved to treat depression and obsessive-compulsive disorder in adults; and estrogen. "That learning and memory can be corrected in adult Ts65Dn mice is hugely important," Dr. Gardiner said. "This occurs in a brain that has carried trisomy from conception." THE DRAWBACKS OF MOUSE MODELING "Ts65Dn has vastly increased our understanding and predictions of the cellular, molecular, physiological, and behavioral deficits in Down syndrome," Dr. Gardiner said. "However, as a model for testing drug efficacy, the Ts65Dn needs to be judged critically." She outlined a number of problems posed by Ts65Dn: Incomplete Trisomy Ts65Dn carries three copies of only 88 of the 161 protein-encoding genes on human chromosome 21, leaving 73 triplicated human genes unaccounted for in research. The model also carries three copies of 50 genes that are not triplicated in people with Down syndrome. According to Dr. Gardiner, researchers largely have not considered those 50 genes and their potential influences in studies conducted to date. "When a feature is seen in the Ts65Dn, no matter how similar it appears to a feature seen in humans with Down syndrome, it is not known whether it is caused by one or more of the 88 chromosome 21 genes, one or more of the 50 nonchromosome 21 genes, or a combination of both," Dr. Gardiner said. "This also means that we do not know if a drug response seen in Ts65Dn would be the same in a human with full trisomy." DESPITE MANY SHORTCOMINGS, MICE GENETICALLY ENGINEERED TO EXHIBIT THE SAME CHARACTERISTICS AS PEOPLE WITH DOWN SYNDROME ARE THE MOST COMMONLY USED TOOLS IN PRECLINICAL DOWN SYNDROME RESEARCH. THE PROS AND CONS OF MOUSE MODELING CONTINUED ON PAGE 10 SUMMER2015 DOWN SYNDROME WORLD 8

